Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma

Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12–15% of childhood cancer deaths. Although current treatments are relatively efficacious against this cancer, associated adverse effects could be detrimental to growth and development. In contrast, glioblastoma accounts for 52% of brain tumours and has an extremely poor prognosis. Current chemotherapeutics include temozolomide, which has numerous negative side-effects and a low-effective rate. Previous studies have shown the manipulation of autophagy to be a promising method for targeting cancers, including glioblastoma. We sought to determine the effects of autophagic alterations in combination with current chemotherapies in both neuroblastoma and glioblastoma. Supplementing cisplatin or temozolomide with autophagy activator rapamycin stabilized cancer cell mitochondria, despite having little effect on apoptosis or oxidative stress. Autophagy inhibition via 3-methyladenine or hydroxychloroquine alongside standard chemotherapies enhanced apoptosis and oxidative stress, with 3-methyladenine also disrupting mitochondrial health. Importantly, combining hydroxychloroquine with 0.5 µM cisplatin or 50 µg/mL temozolomide was as or more effective than 2 µM cisplatin or 100 µg/mL temozolomide alone. Analyzing these interesting results, a combined treatment of autophagy inhibitor with a standard chemotherapeutic agent could help to improve patient prognosis and reduce chemotherapy doses and their associated side-effects.

[1]  T. Cloughesy,et al.  Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids , 2020, iScience.

[2]  J. Hsieh,et al.  Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma , 2020, Cell Death & Disease.

[3]  Wei Zheng,et al.  Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma , 2020, Oncology letters.

[4]  S-Y Wang,et al.  LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis. , 2020, European review for medical and pharmacological sciences.

[5]  A. D. Tangutur,et al.  Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells , 2020, Molecular and Cellular Biochemistry.

[6]  Zhen-hua Hu,et al.  miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway , 2019, Cell cycle.

[7]  Ji-cheng Tantai,et al.  Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7 , 2019, Cell Death & Disease.

[8]  Yuan Cheng,et al.  Targeting the Mitotic Catastrophe Signaling Pathway in Cancer , 2015, Mediators of inflammation.

[9]  J. Klaunig Oxidative Stress and Cancer. , 2019, Current pharmaceutical design.

[10]  C. James,et al.  MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy , 2019, Autophagy.

[11]  Gong Yang,et al.  Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy , 2019, Theranostics.

[12]  Xiaokun Lin,et al.  Rapamycin inhibits proliferation and induces autophagy in human neuroblastoma cells , 2018, Bioscience reports.

[13]  Yu Liu,et al.  Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer , 2018, Theranostics.

[14]  Matthew A. Taylor,et al.  Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma , 2018, Apoptosis.

[15]  Xingdong Zhou,et al.  Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion , 2018, Autophagy.

[16]  J. Kraveka,et al.  Updates in Diagnosis, Management, and Treatment of Neuroblastoma. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  A. Tamimi,et al.  Epidemiology and Outcome of Glioblastoma , 2017 .

[18]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[19]  M. Kashyap,et al.  Autophagy Activation Alleviates Amyloid-β-Induced Oxidative Stress, Apoptosis and Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells , 2017, Neurotoxicity Research.

[20]  T. Hudlický,et al.  Cancer Cell Mitochondria Targeting by Pancratistatin Analogs is Dependent on Functional Complex II and III , 2017, Scientific Reports.

[21]  Xiaoyan Wang,et al.  Systemic application of 3-methyladenine markedly inhibited atherosclerotic lesion in ApoE−/− mice by modulating autophagy, foam cell formation and immune-negative molecules , 2016, Cell Death & Disease.

[22]  E. Haddad,et al.  Autophagy is associated with chemoresistance in neuroblastoma , 2016, BMC Cancer.

[23]  M. Davis Glioblastoma: Overview of Disease and Treatment. , 2016, Clinical journal of oncology nursing.

[24]  E. White,et al.  Mitochondria and Cancer. , 2016, Molecular cell.

[25]  P. Lam,et al.  Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status , 2015, BMC Cancer.

[26]  K. Tamura,et al.  [Side effects of chemotherapy]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[27]  Thomas C. Chen,et al.  Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. , 2014, Neurosurgical focus.

[28]  Jill S. Barnholtz-Sloan,et al.  Epidemiologic and Molecular Prognostic Review of Glioblastoma , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[29]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[30]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[31]  P. Bischoff,et al.  The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. , 2013, Anticancer research.

[32]  F. Sinicrope,et al.  The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.

[33]  F. Sinicrope,et al.  Autophagy modulation for cancer therapy , 2011, Cancer biology & therapy.

[34]  Sandra Barth,et al.  Autophagy: cellular and molecular mechanisms , 2010, The Journal of pathology.

[35]  H. Caron,et al.  Neuroblastoma: biology, prognosis, and treatment. , 2010, Hematology/oncology clinics of North America.

[36]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[37]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[38]  I. Germano,et al.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells , 2004, Cell Death and Differentiation.

[39]  P. Seglen,et al.  3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Weller,et al.  Chapter 23 - Glioblastoma , 2016 .

[41]  M. Stevens,et al.  Temozolomide: mechanisms of action, repair and resistance. , 2012, Current molecular pharmacology.

[42]  D. Rubinsztein,et al.  Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies , 2009, Cell Death and Differentiation.

[43]  S. Weinhouse On respiratory impairment in cancer cells. , 1956, Science.